Clinical utility gene card for: Multiple endocrine neoplasia type 2

European Journal of Human Genetics

Volumn 20, Issue 1, 2012, Pages 128-

  Raue, Friedhelm ^a   Rondot, Susanne ^a   Schulze, Egbert ^a   Szpak Ulczok, Sylwia ^b   Jarzab, Barbara ^b   Frank Raue, Karin ^a  

^a Endocrine Practice and Molecular Laboratory   (Germany)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC SCREENING; HUNTER SYNDROME; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRENATAL DIAGNOSIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEQUENCE ANALYSIS; DIFFERENTIAL DIAGNOSIS; FAMILIAL CANCER; GENETICS; GENOTYPE; HUMAN; METHODOLOGY; NEUROFIBROMATOSIS; POINT MUTATION; SENSITIVITY AND SPECIFICITY; SIPPLE SYNDROME; THYROID TUMOR;

DIAGNOSIS, DIFFERENTIAL; GENETIC TESTING; GENOTYPE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; NEOPLASTIC SYNDROMES, HEREDITARY; POINT MUTATION; PRENATAL DIAGNOSIS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 83255185146     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2011.142     Document Type: Article

References (16)

1. Kloos RT, Eng C, Evans DB et al: Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19: 565-612.
2. Frank-Raue K, Rondot S, Raue F: Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC. Mol Cell Endocrinol 2010; 322: 2-7.
3. Elisei R, Romei C, Cosci B et al: RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007; 92: 4725-4729. (Pubitemid 350223450)
4. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM: RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006; 27: 535-560. (Pubitemid 44213230)
5. Romei C, Mariotti S, Fugazzola L et al: Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol 2010; 163: 301-308.
6. Machens A, Niccoli-Sire P, Hoegel J et al: Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003; 349: 1517-1525. (Pubitemid 37255037)
7. Frank-Raue K, Rybicki LA, Erlic Z et al: Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat 2010; 32: 51-58.
8. Raue F, Frank-Raue K: Update multiple endocrine neoplasia type 2. Fam Cancer 2010; 9: 449-457.
9. Brandi ML, Gagel RF, Angeli A et al: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-5671. (Pubitemid 33152604)
10. Wiench M, Wygoda Z, Gubala E et al: Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol 2001; 19: 1374-1380. (Pubitemid 32202543)
11. Hansford JR, Mulligan LM: Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000; 37: 817-827.
12. Brooks AS, Oostra BA, Hofstra RM: Studying the genetics of Hirschsprung's disease: unraveling an oligogenic disorder. Clin Genet 2005; 67: 6-14.
13. Wang TS, Ocal IT, Sosa JA, Cox H, Roman S: Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma. Thyroid 2008; 18: 889-894.
14. Dora JM, Canalli MH, Capp C, Punales MK, Vieira JG, Maia AL: Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. Thyroid 2008; 18: 895-899.
15. Raue F, Kraimps JL, Dralle H et al: Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 1995; 238: 369-373.
16. Pacak K, Eisenhofer G, Ilias I: Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones (Athens) 2009; 8: 111-116.